The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection

Frontiers in Immunology

关键词: Helicobacter pylori;    cancer;    immunotherapy;    personalized medicine;    gut microbiota;    immune checkpoint inhibitors;   

DOI  :  10.3389/fimmu.2022.899161

来源: DOAJ

【 摘 要 】

Helicobacter pylori infects the gastric mucosa of a large number of humans. Although asymptomatic in the vast majority of cases, H pylori infection can lead to the development of peptic ulcers gastric adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma. Using a variety of mechanisms, H pylori locally suppresses the function of the host immune system to establish chronic infection. Systemic immunomodulation has been observed in both clinical and pre-clinical studies, which have demonstrated that H pylori infection is associated with reduced incidence of inflammatory diseases, such as asthma and Crohn’s disease. The introduction of immunotherapies in the arsenal of anti-cancer drugs has revealed a new facet of H pylori-induced immune suppression. In this review, we will describe the intimate interactions between H pylori and its host, and formulate hypothtyeses describing the detrimental impact of H pylori infection on the efficacy of cancer immunotherapies.

【 授权许可】

Unknown